Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

M. Gadgeel, Shirish; Rodríguez‐Abreu, Delvys; Speranza, Giovanna; Esteban, Emilio; Felip, Enriqueta; Dómine, Manuel; Hui, Rina; J. Hochmair, Maximilian; R. Clingan, Philip; Powell, Steven; Y. Cheng, Susanna; Bischoff, Helge; Peled, Nir; Grossi, Francesco; Jennens, Ross; Reck, Martin; B. Garon, Edward; Novello, Silvia; Rubio‐Viqueira, Belén; Boyer, Michael; Kurata, Takayasu; E. Gray, Jhanelle; Yang, Jing; Öcek Baş, Tuba; Catherine Pietanza, M.; Chiara Garassino, Marina

doi:10.1200/jco.19.03136

Public

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • Mar 9, 2020

Authors:

Shirish M. Gadgeel

Delvys Rodríguez‐Abreu

Giovanna Speranza

Abstract

PURPOSE: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor...

Subject

Pemetrexed

Medicine

Pembrolizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!